Trichomoniasis Market Insights, Epidemiology, and Market Forecast–2030 (US)
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Trichomoniasis Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Trichomoniasis in the United States.
The Trichomoniasis market report provides analysis regarding current treatment practices, an emerging drug, like Secnidazole (Lupin Research Inc), potential therapies, market share of the individual therapies, historical, current, and forecasted Trichomoniasis market size from 2017 to 2030 for the United States.
The report also covers current Trichomoniasis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the market’s underlying potential.
Geography Covered
Trichomoniasis – Disease Understanding and Treatment Algorithm
Trichomoniasis Overview
Trichomoniasis (TRIK-uh-muh-NEYE-uh-suhss) or “trich” is a sexually transmitted infection (STI) caused by a parasite; the parasite is spread most often through vaginal, oral, or anal sex. The condition has various public health ramifications and has been associated with vaginitis, cervicitis, urethritis, and pelvic inflammatory disease (PID). Furthermore, it is one of the most common STIs in the United States and affects more women than men. Although it is treated easily with antibiotics, many women do not show any symptoms.
Symptoms can come and go but about 70% of infected people do not have any signs or symptoms. When trichomoniasis does cause symptoms, they can range from mild irritation to severe inflammation. Some people with symptoms get them within 5–28 days after being infected, but others do not develop symptoms until much later. The reason for this is unclear.
Trichomoniasis Treatment
This chapter covers the details of conventional and current medical therapies available in the Trichomoniasis market to treat the condition. It also provides the country-wise Trichomoniasis treatment guidelines across the United States.
DelveInsight’s Trichomoniasis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Trichomoniasis treatment algorithms and treatment guidelines in the US.
Trichomoniasis Epidemiology
The Trichomoniasis epidemiology chapters provide insights about historical and current Trichomoniasis patient pool and forecasted trends for the US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Trichomoniasis epidemiology is segmented by Diagnosed Prevalent Cases of Trichomoniasis, Gender-specific Cases of Trichomoniasis, Cases of Trichomoniasis by Age and Type-specific Cases of Trichomoniasis. The report includes a thorough analysis of all segmentations.
In the US, the cases of Trichomoniasis were 2,570,002 in 2017. Moreover, the Gender-specific cases of Trichomoniasis were highest among females and were reported to be 2,073,893 in the country.
According to DelveInsight’s analysis, In the United States, the highest number of Trichomoniasis cases are among 40–49 years of age group followed by 30–39 years.
In the United States, approximately 70% of the Trichomoniasis cases are asymptomatic.
Trichomoniasis Drug Chapters
The drug chapter segment of the Trichomoniasis report encloses the detailed analysis of Trichomoniasis pipeline drug. It also helps understand the Trichomoniasis clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.
Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Trichomoniasis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Secnidazole (Lupin Research Inc), etc., for the treatment of Trichomoniasis in the pipeline.
Trichomoniasis Market Outlook
The Trichomoniasis market size is expected to increase at a significant CAGR during the study period (2017–2030). The United States accounts for the Trichomoniasis market size, with USD 30.8 million in 2017.
Trichomoniasis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs in the Trichomoniasis market that are expected to get launched in the market during the study period 2017–2030. The analysis covers Trichomoniasis market uptake by drugs, patient uptake by therapies, and sale of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Trichomoniasis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.
Trichomoniasis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Trichomoniasis key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of Trichomoniasis collaborations, acquisition and merger, licensing, patent details, and other information for Trichomoniasis emerging therapies.
Reimbursement Scenario in Trichomoniasis
Approaching reimbursement, proactively, can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Trichomoniasis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Trichomoniasis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Report Highlights
Market Insights:
DelveInsight estimates an increase in Trichomoniasis Market Size during the study period, 2017–2030
What are the present Trichomoniasis market drivers?
Increasing Prevalence for Trichomoniasis infection and associated complications and increasing demand for Rapid Test Kits and Point of Care
What are the Trichomoniasis market barriers?
Resistance against the standard of care, Epidemiological Data for T. vaginalis Infection and Economic Burden of Trichomoniasis.
How many companies are developing drugs for Trichomoniasis?
Currently, there are many key pharma players engaged in developing the drug for Trichomoniasis in monotherapy.
Which are the leading companies in Trichomoniasis market?
Key Players – Lupin Research Inc
How is epidemiology segmented for Trichomoniasis?
Prevalent Cases of Trichomoniasis, Trichomoniasis cases by Gender, Trichomoniasis cases by Age and Trichomoniasis cases by types.
DelveInsight’s ‘Trichomoniasis Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Trichomoniasis in the United States.
The Trichomoniasis market report provides analysis regarding current treatment practices, an emerging drug, like Secnidazole (Lupin Research Inc), potential therapies, market share of the individual therapies, historical, current, and forecasted Trichomoniasis market size from 2017 to 2030 for the United States.
The report also covers current Trichomoniasis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the market’s underlying potential.
Geography Covered
- The United States
Trichomoniasis – Disease Understanding and Treatment Algorithm
Trichomoniasis Overview
Trichomoniasis (TRIK-uh-muh-NEYE-uh-suhss) or “trich” is a sexually transmitted infection (STI) caused by a parasite; the parasite is spread most often through vaginal, oral, or anal sex. The condition has various public health ramifications and has been associated with vaginitis, cervicitis, urethritis, and pelvic inflammatory disease (PID). Furthermore, it is one of the most common STIs in the United States and affects more women than men. Although it is treated easily with antibiotics, many women do not show any symptoms.
Symptoms can come and go but about 70% of infected people do not have any signs or symptoms. When trichomoniasis does cause symptoms, they can range from mild irritation to severe inflammation. Some people with symptoms get them within 5–28 days after being infected, but others do not develop symptoms until much later. The reason for this is unclear.
Trichomoniasis Treatment
This chapter covers the details of conventional and current medical therapies available in the Trichomoniasis market to treat the condition. It also provides the country-wise Trichomoniasis treatment guidelines across the United States.
DelveInsight’s Trichomoniasis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Trichomoniasis treatment algorithms and treatment guidelines in the US.
Trichomoniasis Epidemiology
The Trichomoniasis epidemiology chapters provide insights about historical and current Trichomoniasis patient pool and forecasted trends for the US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Trichomoniasis epidemiology is segmented by Diagnosed Prevalent Cases of Trichomoniasis, Gender-specific Cases of Trichomoniasis, Cases of Trichomoniasis by Age and Type-specific Cases of Trichomoniasis. The report includes a thorough analysis of all segmentations.
In the US, the cases of Trichomoniasis were 2,570,002 in 2017. Moreover, the Gender-specific cases of Trichomoniasis were highest among females and were reported to be 2,073,893 in the country.
According to DelveInsight’s analysis, In the United States, the highest number of Trichomoniasis cases are among 40–49 years of age group followed by 30–39 years.
In the United States, approximately 70% of the Trichomoniasis cases are asymptomatic.
Trichomoniasis Drug Chapters
The drug chapter segment of the Trichomoniasis report encloses the detailed analysis of Trichomoniasis pipeline drug. It also helps understand the Trichomoniasis clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.
Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Trichomoniasis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Secnidazole (Lupin Research Inc), etc., for the treatment of Trichomoniasis in the pipeline.
Trichomoniasis Market Outlook
The Trichomoniasis market size is expected to increase at a significant CAGR during the study period (2017–2030). The United States accounts for the Trichomoniasis market size, with USD 30.8 million in 2017.
Trichomoniasis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs in the Trichomoniasis market that are expected to get launched in the market during the study period 2017–2030. The analysis covers Trichomoniasis market uptake by drugs, patient uptake by therapies, and sale of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Trichomoniasis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.
Trichomoniasis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Trichomoniasis key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of Trichomoniasis collaborations, acquisition and merger, licensing, patent details, and other information for Trichomoniasis emerging therapies.
Reimbursement Scenario in Trichomoniasis
Approaching reimbursement, proactively, can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Trichomoniasis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Trichomoniasis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Report Highlights
- In the coming years, Trichomoniasis market scenario is expected to alter across the USA due to the launch of novel therapies with new mechanisms of action considering the high unmet medical need.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
- Patient Population
- Therapeutic Approaches
- Trichomoniasis Pipeline Analysis
- Trichomoniasis Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 11 years Forecast
- The United States Coverage
- Trichomoniasis Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
Market Insights:
- What was the Trichomoniasis market share (%) distribution in 2017, and how it would look like in 2030?
- What would be the Trichomoniasis total market size as well as market size by therapies across the United States during the forecast period (2017–2030)?
- What are the key findings pertaining to the market across the United States, and which country will have the largest Trichomoniasis market size during the forecast period (2017–2030)?
- At what CAGR, the Trichomoniasis market is expected to grow in the United States during the forecast period (2017–2030)?
- What would be the Trichomoniasis market outlook across the United States during the forecast period (2017–2030)?
- What would be the Trichomoniasis market growth until 2030, and what will be the resultant market Size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What is the disease risk, burden, and unmet needs of Trichomoniasis?
- What is the historical Trichomoniasis patient pool in the United States?
- What would be the forecasted patient pool of Trichomoniasis in the United States?
- What will be the growth opportunities in the United States with respect to the patient population pertaining to Trichomoniasis?
- At what CAGR the population is expected to grow in the USA during the forecast period (2017–2030)?
- What are the current options for the Trichomoniasis treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Trichomoniasis in the USA?
- What is the Trichomoniasis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of Trichomoniasis?
- How many therapies are developed by each company for Trichomoniasis treatment?
- How many are emerging therapies in mid-stage and late-stage of development for Trichomoniasis treatment?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Trichomoniasis therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Trichomoniasis and their status?
- What are the key designations that have been granted for the emerging therapies for Trichomoniasis?
- What are the global historical and forecasted market of Trichomoniasis?
- The report will help in developing business strategies by understanding trends shaping and driving the Trichomoniasis market
- To understand the future market competition in the Trichomoniasis market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Trichomoniasis in the United States.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- To understand the future market competition in the Trichomoniasis market
DelveInsight estimates an increase in Trichomoniasis Market Size during the study period, 2017–2030
What are the present Trichomoniasis market drivers?
Increasing Prevalence for Trichomoniasis infection and associated complications and increasing demand for Rapid Test Kits and Point of Care
What are the Trichomoniasis market barriers?
Resistance against the standard of care, Epidemiological Data for T. vaginalis Infection and Economic Burden of Trichomoniasis.
How many companies are developing drugs for Trichomoniasis?
Currently, there are many key pharma players engaged in developing the drug for Trichomoniasis in monotherapy.
Which are the leading companies in Trichomoniasis market?
Key Players – Lupin Research Inc
How is epidemiology segmented for Trichomoniasis?
Prevalent Cases of Trichomoniasis, Trichomoniasis cases by Gender, Trichomoniasis cases by Age and Trichomoniasis cases by types.
1. KEY INSIGHTS
2. EXECUTIVE SUMMARY OF TRICHOMONIASIS
3. SWOT ANALYSIS FOR TRICHOMONIASIS
4. DISEASE BACKGROUND AND OVERVIEW
4.1. Introduction
4.2. Cause
4.3. Symptoms
4.4. Pathogenesis
4.5. Immune response against trichomoniasis
4.6. Risk Factors
4.7. Clinical presentation
4.8. Diagnosis
5. EPIDEMIOLOGY AND PATIENT POPULATION
5.1. Key Findings
5.2. Assumptions and Rationale – United States
5.3. The United States
5.3.1. Diagnosed Prevalent Cases of Trichomoniasis in the United States
5.3.2. Gender-specific Cases of Trichomoniasis in the United States
5.3.3. Age-specific Cases of Trichomoniasis in the United States
5.3.4. Type-specific Cases of Trichomoniasis by Symptoms in the United States
6. TREATMENT
7. GUIDELINES
7.1. Trichomoniasis: Diagnostic and Treatment Guidelines by CDC
8. UNMET NEEDS
9. ORGANIZATIONS CONTRIBUTING TOWARD TRICHOMONIASIS
10. CASE REPORTS
10.1. A Missed Diagnosis of Trichomoniasis
10.2. A Resistant Case of Familial Nonsexual Transmission of Trichomonas
10.3. The Tricky Trichomonas: A Tale of Resistance
11. PATIENT JOURNEY
11.1. Patient Journey: General
12. MARKETED THERAPIES
13. EMERGING THERAPIES
13.1. Secnidazole: Lupin Research Inc
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
14. TRICHOMONIASIS: MARKET ANALYSIS
14.1. Key Findings
14.2. Market Outlook: The United States
14.2.1. The United States Market Size
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Bibliography
17.2. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
2. EXECUTIVE SUMMARY OF TRICHOMONIASIS
3. SWOT ANALYSIS FOR TRICHOMONIASIS
4. DISEASE BACKGROUND AND OVERVIEW
4.1. Introduction
4.2. Cause
4.3. Symptoms
4.4. Pathogenesis
4.5. Immune response against trichomoniasis
4.6. Risk Factors
4.7. Clinical presentation
4.8. Diagnosis
5. EPIDEMIOLOGY AND PATIENT POPULATION
5.1. Key Findings
5.2. Assumptions and Rationale – United States
5.3. The United States
5.3.1. Diagnosed Prevalent Cases of Trichomoniasis in the United States
5.3.2. Gender-specific Cases of Trichomoniasis in the United States
5.3.3. Age-specific Cases of Trichomoniasis in the United States
5.3.4. Type-specific Cases of Trichomoniasis by Symptoms in the United States
6. TREATMENT
7. GUIDELINES
7.1. Trichomoniasis: Diagnostic and Treatment Guidelines by CDC
8. UNMET NEEDS
9. ORGANIZATIONS CONTRIBUTING TOWARD TRICHOMONIASIS
10. CASE REPORTS
10.1. A Missed Diagnosis of Trichomoniasis
10.2. A Resistant Case of Familial Nonsexual Transmission of Trichomonas
10.3. The Tricky Trichomonas: A Tale of Resistance
11. PATIENT JOURNEY
11.1. Patient Journey: General
12. MARKETED THERAPIES
13. EMERGING THERAPIES
13.1. Secnidazole: Lupin Research Inc
13.1.1. Product Description
13.1.2. Other Development Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
14. TRICHOMONIASIS: MARKET ANALYSIS
14.1. Key Findings
14.2. Market Outlook: The United States
14.2.1. The United States Market Size
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Bibliography
17.2. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Summary of Trichomoniasis Market, Epidemiology, and Key Events (2017–2030)
Table 2: Diagnostic Clues for Vaginal Infections
Table 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017–2030)
Table 4: Gender-specific Cases of Trichomoniasis in the United States (2017–2030)
Table 5: Age-specific Cases of Trichomoniasis in the United States (2017–2030)
Table 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017–2030)
Table 7: Options for Treating Metronidazole-Resistant Trichomoniasis
Table 8: Organizations contributing to Trichomoniasis in the United States
Table 9: Secnidazole, Clinical Trial Description, 2020
Table 10: United States Market Size of Trichomoniasis in USD Million (2017–2030)
Table 11: The US Market Size of Trichomoniasis by Therapies in USD Million (2017–2030)
Table 1: Summary of Trichomoniasis Market, Epidemiology, and Key Events (2017–2030)
Table 2: Diagnostic Clues for Vaginal Infections
Table 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017–2030)
Table 4: Gender-specific Cases of Trichomoniasis in the United States (2017–2030)
Table 5: Age-specific Cases of Trichomoniasis in the United States (2017–2030)
Table 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017–2030)
Table 7: Options for Treating Metronidazole-Resistant Trichomoniasis
Table 8: Organizations contributing to Trichomoniasis in the United States
Table 9: Secnidazole, Clinical Trial Description, 2020
Table 10: United States Market Size of Trichomoniasis in USD Million (2017–2030)
Table 11: The US Market Size of Trichomoniasis by Therapies in USD Million (2017–2030)
LIST OF FIGURES
Figure 1: SWOT Analysis
Figure 2: Overview of Diagnostic Assays for Trichomoniasis
Figure 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017–2030)
Figure 4: Gender-specific Cases of Trichomoniasis in the United States (2017–2030)
Figure 5: Age-specific Cases of Trichomoniasis in the United States (2017–2030)
Figure 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017–2030)
Figure 7: Unmet Needs of Trichomoniasis
Figure 8: Market Size of Trichomoniasis in the United States, USD Million (2017–2030)
Figure 9: The US Market Size of Trichomoniasis by Therapies in USD Million (2017–2030)
Figure 10: Market Drivers of Trichomoniasis
Figure 11: Market Drivers of Trichomoniasis
Figure 1: SWOT Analysis
Figure 2: Overview of Diagnostic Assays for Trichomoniasis
Figure 3: Diagnosed Prevalent Cases of Trichomoniasis in the United States (2017–2030)
Figure 4: Gender-specific Cases of Trichomoniasis in the United States (2017–2030)
Figure 5: Age-specific Cases of Trichomoniasis in the United States (2017–2030)
Figure 6: Type-specific Cases of Trichomoniasis by Symptoms in the United States (2017–2030)
Figure 7: Unmet Needs of Trichomoniasis
Figure 8: Market Size of Trichomoniasis in the United States, USD Million (2017–2030)
Figure 9: The US Market Size of Trichomoniasis by Therapies in USD Million (2017–2030)
Figure 10: Market Drivers of Trichomoniasis
Figure 11: Market Drivers of Trichomoniasis
